Abstract Alzheimer's disease (AD) research has entered a new era where public‐private partnerships are reigniting the pursuit of disease‐modifying therapies targeting mechanisms beyond amyloid and tau. This perspective outlines how Monument Biosciences was founded to advance novel therapies by translating National Institutes of Health (NIH) ‐supported discoveries from the TaRget Enablement to Accelerate Therapy Development for AD (TREAT‐AD) and the Model Organism Development and Evaluation for Late‐onset AD (MODEL‐AD) consortia into a venture‐backed pipeline focused on neuroinflammation. Monument Bio strategically builds on genetic validation and high‐quality, nondilutive‐funded research and serves as a case study in how academic research can reduce risk in early‐stage biotech development to advance novel therapies. The company exemplifies a novel academic‐startup collaboration model, emphasizing robust biomarker strategies to streamline clinical development. Aligned with the framework presented by Richardson et al. , in this issue, this approach supports a new generation of neuroscience companies grounded in open science, strong target validation, and disease‐relevant endpoints. Highlights The Alzheimer's field is poised for next‐generation therapies beyond amyloid and tau. Monument Bio translates National Institutes of Health (NIH)‐supported science into a venture‐backed Alzheimer's pipeline. TaRget Enablement to Accelerate Therapy Development for AD (TREAT‐AD) and Model Organism Development and Evaluation for Late‐onset AD (MODEL‐AD) de‐risk programs with validated assays, probes, and biomarker tools. Monument Bio shows how TREAT‐AD's Target Enabling Packages (TEPs) enable difficult targets. Integrated biomarkers enable predictive translation, faster approval, and investment rationale.
Giardina et al. (2026) studied this question.